title: Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled Trial.
abstract: Objective. Report of prespecified and post hoc subgroup analyses of a randomized, controlled trial comparing telmisartan 80 mg/hydrochlorothiazide 25 mg (T80/H25) combination therapy with T80 monotherapy, according to the presence of cardiovascular disease (CVD) risk factors. Methods. Hypertensive patients were randomized (2 : 1) to receive T80/H25 or T80 for 6 weeks, following a 1-week, low-dose, and run-in period. Systolic blood pressure (SBP) and diastolic BP reductions and BP goal achievement were evaluated in patients with CVD risk factors: presence of diabetes mellitus (DM), renal impairment, increased body mass index (BMI), and 10-year estimated risk for coronary heart disease (CHD). Results. In total, 888 patients received treatment. Overall, T80/H25 therapy significantly reduced SBP more than T80 monotherapy, irrespective of patient subgroup. In patients with DM, renal impairment, high BMI, and high CHD risk, BP goal achievement rates (<140/90 mm Hg) at Week 7, among those treated with T80/H25, were 52.8%, 52.8%, 50.6%, and 38.5%, respectively. More patients with DM reached a guideline-based BP goal (<130/80 mm Hg) at 7 weeks with T80/H25 than with T80 monotherapy (16.7% versus 8.8%). Rates of treatment-related adverse events were low and comparable across patient subgroups. Conclusions. Antihypertensive treatment with T80/H25 single-pill combination is effective and generally well tolerated, irrespective of the presence of CVD risk factors.
authors: Louisville Metabolic and Atherosclerosis Research Center Inc. (L-MARC), 3288 Illinois Avenue, Louisville, KY 40213, USA.
authors: Harold
authors: H
authors: Bays
authors: Pingjin
authors: P
authors: Gao
authors: Birgit
authors: B
authors: Völker
authors: Michaela
authors: M
authors: Mattheus
authors: Luis M
authors: LM
authors: Ruilope
authors: Dingliang
authors: D
authors: Zhu
references: J Hum Hypertens. 2009 Jan;23(1):4-11
references: 18615100
references: Eur Heart J. 2011 Oct;32(20):2499-506
references: 21697169
references: J Am Soc Hypertens. 2010 Jan-Feb;4(1):42-50
references: 20374950
references: Nephrol Dial Transplant. 2006 Jun;21(6):1469-73
references: 16714336
references: J Hypertens. 2007 Jun;25(6):1105-87
references: 17563527
references: J Hypertens. 2009 Nov;27(11):2121-58
references: 19838131
references: Clin Ther. 2012 Jul;34(7):1613-24
references: 22717420
references: Circulation. 1998 May 12;97(18):1837-47
references: 9603539
references: Circulation. 2002 Dec 17;106(25):3143-421
references: 12485966
references: Lancet. 2001 Oct 20;358(9290):1305-15
references: 11684211
references: Hypertension. 2003 Dec;42(6):1206-52
references: 14656957
references: J Hypertens. 2012 Jan;30(1):188-93
references: 22134390
references: J Hypertens. 2008 Apr;26(4):819-24
references: 18327094
references: Expert Rev Clin Pharmacol. 2011 Mar;4(2):151-61
references: 22115399
references: N Engl J Med. 2008 Apr 10;358(15):1547-59
references: 18378520
references: J Hypertens. 2007 Sep;25(9):1751-62
references: 17762635
references: Hypertension. 2005 Jan;45(1):142-61
references: 15611362
references: J Clin Hypertens (Greenwich). 2008 Aug;10(8):624-31
references: 18772645